Filing Details

Accession Number:
0001209191-20-058464
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-11-16 16:19:34
Reporting Period:
2020-11-13
Accepted Time:
2020-11-16 16:19:34
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1604464 Atara Biotherapeutics Inc. ATRA Biological Products, (No Disgnostic Substances) (2836) 460920988
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1702457 Joe Newell C/O Atara Biotherapeutics, Inc.
611 Gateway Blvd., Suite 900
South San Francisco CA 94080
Chief Operations Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-11-13 3,500 $12.15 125,703 No 4 M Direct
Common Stock Disposition 2020-11-13 6,200 $18.36 119,503 No 4 S Direct
Common Stock Disposition 2020-11-13 1,300 $19.12 118,203 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2020-11-13 2,833 $0.00 2,833 $12.15
Common Stock Employee Stock Option (Right to Buy) Disposition 2020-11-13 667 $0.00 667 $12.15
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
50,167 2030-02-28 No 4 M Direct
16,333 2030-02-28 No 4 M Direct
Footnotes
  1. Transaction pursuant to Rule 10b5-1 Plan adopted September 14, 2020.
  2. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.84 to $18.74. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  3. The price in Column 4 is a weighted average sale price. The prices actually received ranged from $18.85 to $19.18. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  4. 1/48th of the shares subject to the stock option vest and become exercisable each month with the initial installment vesting on April 1, 2020, subject to the reporting person's continuous service.